FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WITTE OWEN N.						2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO]								Relationship leck all appli X Direct	cable) or	g Pers	10% Ov	vner	
(Last) 210 EAS	(F T GRAND	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022								Office below	r (give title)		Other (s below)	specify	
(Street) SOUTH FRANCI	TH SAN CA 94080					4. If Amendment, Date of Original Filed (Month/Day/Year)								e) X Form Form	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)	Davis		tive Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)				saction	ction 2A. Deemed Execution Date,			3. Transa	ction	4. Securi	ities Acquir d Of (D) (Ins	ed (A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock 06/15					5/202	/2022			Code	v	Amount	(A) o (D)	r Price	Transac (Instr. 3	ion(s) and 4)		D	(1110411.4)	
Common	Common Stock 06/15/2022																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		•	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code		v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$9.62	06/15/2022			A		35,535		(1)	C	06/15/2032	Common Stock	35,535	\$0	35,53	5	D		

Explanation of Responses:

1. Vesting in 12 equal monthly installments.

Remarks:

/s/ Veer Bhavnagri, Attorney-

06/17/2022

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.